Skip to main content

Drug Interaction Report

2 potential interactions and/or warnings found for the following 2 drugs:

Filter by interaction and/or warning

Interactions between your drugs

Major

pentamidine zalcitabine

Applies to: pentamidine, Hivid (zalcitabine)

GENERALLY AVOID: Coadministration of intravenous pentamidine with didanosine or zalcitabine may increase the risk of pancreatitis. These drugs have individually been associated with pancreatitis and additive toxicity may occur during concomitant use. Fatalities have been reported.

MANAGEMENT: The manufacturer recommends that the antiretroviral drugs should be interrupted, if clinically feasible, when treatment with intravenous pentamidine is initiated. If concomitant use cannot be avoided, patients should be closely monitored for clinical and laboratory signs of pancreatitis.

References (2)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."

Drug and food interactions

Minor

zalcitabine food

Applies to: Hivid (zalcitabine)

Zalcitabine bioavailability may be decreased by 14% if taken with meals. The mechanism and clinical significance are unknown.

References (1)
  1. (2001) "Product Information. HIVID (zalcitabine)." Roche Laboratories

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.